Examkin

Soru

Zorluk: Çok zorClinical Preventive Services and Screening

A 45-year-old asymptomatic man with no significant past medical history presents for a routine wellness examination. He has not seen a physician in over a decade. He takes no medications and has no known risk factors for viral hepatitis. The physician decides to implement age-appropriate clinical preventive services.

Arrange the following steps in the correct chronological sequence for this patient's Hepatitis C screening and subsequent management, assuming positive or abnormal findings at each diagnostic step.

  1. 1Perform screening with a Hepatitis C virus (HCV) antibody test
  2. 2Obtain an HCV RNA polymerase chain reaction (PCR) assay
  3. 3Assess the degree of hepatic fibrosis using non-invasive methods (e.g., transient elastography or FIB-4 index)
  4. 4Initiate treatment with a pan-genotypic direct-acting antiviral (DAA) regimen
  5. 5Measure HCV RNA levels 12 weeks after the completion of antiviral therapy

Cevap

The correct sequence is: HCV antibody testing, followed by HCV RNA testing, hepatic fibrosis assessment, initiation of DAA therapy, and finally measuring HCV RNA 12 weeks post-treatment.
The standard of care for Hepatitis C screening and management follows a strict clinical cascade. It begins with universal one-time screening using the HCV antibody test for all adults aged 18 to 79. Because antibodies persist even after spontaneous clearance, a positive screen must be followed by an HCV RNA PCR test to confirm active viremia. Once active infection is confirmed, non-invasive assessment of hepatic fibrosis (such as transient elastography or FIB-4) must be performed before starting treatment; this dictates the specific regimen and identifies the need for lifelong hepatocellular carcinoma surveillance in cirrhotic patients. Following fibrosis staging, pan-genotypic direct-acting antiviral (DAA) therapy is initiated. Finally, virologic cure is confirmed by documenting a sustained virologic response (SVR), which requires an undetectable HCV RNA level 12 weeks after therapy completion.

Adım Adım Çözüm

1
Identify the indication for initial screening.
The patient meets criteria for universal one-time HCV screening (adults aged 18-79).
USPSTF guidelines mandate universal screening to detect asymptomatic carriers and reduce long-term morbidity.
2
Determine the confirmatory test following a positive screen.
HCV RNA PCR is ordered.
Antibodies remain positive lifelong even if the infection was spontaneously cleared; RNA confirms active viremia.
3
Identify the mandatory pre-treatment evaluation.
Hepatic fibrosis assessment is performed.
Fibrosis staging dictates the treatment regimen and long-term hepatocellular carcinoma surveillance needs.
4
Select the appropriate therapeutic intervention.
Pan-genotypic DAA therapy is initiated.
DAAs are the standard of care for eradicating confirmed, active HCV infection.
5
Determine the protocol for confirming cure.
HCV RNA is measured 12 weeks post-treatment.
This establishes a Sustained Virologic Response (SVR), which equates to a clinical cure.

Anahtar Kavram

The clinical cascade for Hepatitis C includes universal antibody screening, RNA confirmation of active infection, fibrosis staging prior to treatment, DAA therapy, and documentation of Sustained Virologic Response (SVR).
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

Clinical Preventive Services and Screening

Bu konudan daha fazla soru